[Edaily Reporter NA EUN-KYUNG ] Donghwa Pharmaceutical ( DongwhaPharm(000020)) announced on the 29th that it has appointed Director Kim Ji-yoon as the new Head of the Lifestyle and Health Marketing Division. The Lifestyle and Health Marketing Division, which operates under the Lifestyle and Health Headquarters, oversees the Beauty Marketing Team and the Health Supplement Marketing Team.
Kim Ji-yoon, Head of the Lifestyle and Health Marketing Division at DongwhaPharm (Photo: DongwhaPharm)
Director Kim Ji-yoon is an expert who has led marketing efforts for various brands in the beauty industry. Starting in 2008 as the Head of the Color Cosmetics Business Management (BM) Division at LG H&H(051900), she went on to work at Celltrion Skin Cure and ABLE C&C(078520) ’s Misha, where she was responsible for brand marketing across various cosmetics categories, including color cosmetics and skincare.
In 2020, she joined CHONGKUNDANG Health as a director in the Cosmetics Business Division, leading the cosmetics business of the pharmaceutical affiliate. Director Kim will now oversee the brand strategy and marketing for DongwhaPharm’s beauty and health functional food brands.
A graduate of the Department of Business Administration at Chung-Ang University, Director Kim also contributed to the development of the Cosmetics Product Planning Strategy course at the Korea Health and Welfare Talent Institute in 2018.
Director Kim Ji-yoon stated, “Building on the brand marketing experience accumulated by DongwhaPharm over its 129-year history, I will work to create brands that are trusted and loved by consumers in the beauty and health functional food sectors.”
“Whereas in the past we looked at what not to invest in, now we look at which entrepreneurs to invest in.”A South Korean capital markets official who recently attended an international conference on “…
On the afternoon of the 18th, at the Vuori pop-up store in Seongsu-dong, Seongdong-gu, Seoul, a different scene unfolded as I passed through the first and second floors—where clothes were displayed—an…
AprilBio Co.,Ltd.(397030)has decided to explore other indications for “APB-A1” (Lu AG22515), a technology it licensed to Lundbeck, after the compound failed to demonstrate the expected clinical effica…